Figure 3: miR-29c mediates the regulation of IGF2 on VEGF in fibroblasts.

(a) Base pairing between 3′UTR of VEGF and miR-127-5p and miR-29c, respectively. (b) Quantification of miR-127-5p and miR-29c expressions in IGF2-treated fibroblasts by TagMan miRNA assay. (c) Western blot analysis showing the expression of VEGF in the fibroblasts transfected with miR-127-5p and miR-29c plasmids, respectively. (d) VEGF expression was determined in the fibroblasts transfected with miR-29c or miR-CON in the presence or absence of IGF2. (e) Comparison of miR-29c expression level between CAFs and matched NEFs from 11 ESCC patients (left panel; paired t-test), and correlation with oesophageal tissue IGF2 expression (right panel; Pearson’s rank correlation coefficient). (f) VEGF expression in the fibroblasts transfected with miR-29c mimic (left panel) or inhibitor (right panel). (g) Luciferase activity in fibroblasts co-transfected with miR-29c and wild-type or mutant VEGF 3'UTR luciferase reporter plasmids. (h) miR-29c abrogated the stimulatory effect of IGF2 on migration of fibroblasts (scale bar, 100 μm). Three biological replicates were performed for in vitro assays. Bars, s.d.; *P<0.05; **P<0.01; ***P<0.001 by Student’s t-test.